Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brimo PS DDS · 1 trial · 1 indication
Implants administered during the parent study are evaluated during this study to determine if they have completely degraded. The time frame is evaluated from the point of the first treatment in the parent study.
| Arm | Type | Description |
|---|---|---|
| Brimo PS DDS® 400 μg (2 implants) | EXPERIMENTAL | Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study. |
| Brimo PS DDS® 400 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study. |
| Brimo PS DDS® 200 μg (2 implants) | EXPERIMENTAL | Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study. |
| Brimo PS DDS® 200 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study. |
| Brimo PS DDS® 100 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study. |
| Brimo PS DDS® 50 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study. |
| Sham | SHAM_COMPARATOR | Patients who received sham in a previous study. |
| Name | Type | Description |
|---|---|---|
| Brimo PS DDS® | DRUG | Patients who received Brimo PS DDS® intravitreal implant in a previous study. |
| Sham | OTHER | Patients who recieved sham in a previous study. |
Inclusion Criteria: * Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason * Applicable studies: Prev...
Brimo PS DDS is an investigational small molecule therapy developed by AbbVie Inc. (ticker ABBV) for ophthalmology. It is a posterior segment drug delivery system containing brimonidine tartrate, studied in patients who previously participated in an intravitreal Brimo PS DDS study. It is not approved and remains in clinical development.
Brimo PS DDS targets the alpha-2 adrenergic receptors ADRA2A, ADRA2C, and ADRA2B as an agonist. By activating these receptors, it is designed to modulate pathways relevant to retinal health. The drug is delivered to the posterior segment of the eye via an intravitreal delivery system.
Brimo PS DDS is being developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is responsible for the clinical program, including the completed Phase 2 safety extension study NCT01080209.
Brimo PS DDS is in Phase 2 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The only listed trial, NCT01080209, is a completed Phase 2 safety extension study.
Brimo PS DDS has been studied in one completed Phase 2 trial, NCT01080209, titled "Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System." It enrolled 215 patients across the United States, Australia, Czechia, France, Germany, India, Israel, Italy, Philippines, Portugal, South Korea, and the United Kingdom.
Yes, Brimo PS DDS and Brimo PS DDS® refer to the same investigational product. The registered trademark symbol is simply a notation of the brand name. Both names are used interchangeably for the brimonidine tartrate posterior segment drug delivery system developed by AbbVie.